ProfileGDS5678 / 1416986_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 84% 84% 86% 84% 85% 86% 87% 84% 84% 85% 84% 85% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7898681
GSM967853U87-EV human glioblastoma xenograft - Control 26.2754384
GSM967854U87-EV human glioblastoma xenograft - Control 36.2926584
GSM967855U87-EV human glioblastoma xenograft - Control 46.6715686
GSM967856U87-EV human glioblastoma xenograft - Control 56.2792184
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1877685
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.329786
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.6719987
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2503684
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2228584
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3931685
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.253784
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4288385
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.286385